Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-05-03
2011-05-03
Shafer, Shulamith H (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388150, C530S388100, C530S387100
Reexamination Certificate
active
07935795
ABSTRACT:
The present invention provides a human monoclonal antibody, and antigen-binding portions thereof, capable of binding to human granulocyte-macrophage colony stimulating factor (hGM-CSF) and neutralizing the bioactivity of the hGM-CSF, wherein the anti-hGM-CSF monoclonal antibody has a light chain (L chain) including an amino acid sequence SEQ ID NO:1 and a heavy chain (H chain) including an amino acid sequence SEQ ID NO: 2. Also provided are human monoclonal anti-hGM-CSF antibodies, and antigen-binding portions thereof, characterized by complementarity determining regions (CDRs) or H chain and L chain variable regions related to SEQ ID NO:1 and SEQ ID NO:2. Antibodies, and antigen-binding portions thereof, of the invention are useful in the treatment of diseases associated with overproduction of hGM-CSF, including allergic disease, graft rejection and graft-versus-host disease (GVHD), and autoimmune diseases.
REFERENCES:
patent: 5662138 (1997-09-01), Wang
patent: 7084257 (2006-08-01), Deshpande et al.
patent: 7138501 (2006-11-01), Ruben et al.
patent: 7193069 (2007-03-01), Isogai et al.
patent: 7229784 (2007-06-01), Holtzman et al.
patent: 7282205 (2007-10-01), Schofield et al.
patent: 7326414 (2008-02-01), Bedian et al.
patent: 7361740 (2008-04-01), Hinton et al.
patent: 2003/0103968 (2003-06-01), Amelsberg et al.
patent: 2010/0010202 (2010-01-01), Kucherlapati et al.
patent: 0 265 384 (1988-04-01), None
patent: 0 499 161 (1992-08-01), None
patent: 05-176792 (1993-07-01), None
patent: WO 03/068924 (2003-08-01), None
patent: WO 2005/105844 (2005-11-01), None
patent: WO 2006/111353 (2006-10-01), None
patent: WO 2006/122797 (2006-11-01), None
patent: WO 2007/049472 (2007-05-01), None
patent: WO 2007/092939 (2007-09-01), None
Paul, Fundamental Immunology, 3r˜ Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”.
Rudikoff et al Proc. Natl. Acad. Sci.USA, 79(6):1979-1983, Mar. 1982.
Colman P. M. Research in Immunology, 145:33-36, 1994.
Goodman and Gilman, 10th edition, McGraw-Hill, 2001, p. 3-29.
Bozinovski et al., “Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4,”Amer J Physiol Lung Cell Mol Physiol286(4):L877-L885 (2004).
Fleetwood et al., “Functions of granulocyte-macrophage colony-stimulating factor,”Crit Rev Immunol25(5):405-428 (2005).
Green, L.L., “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies,”J Immunol Meth231(1-2):11-23 (1999).
Griffiths et al., “Strategies for selection of antibodies by phage display,”Curr Opin Biotech9(1):102-108 (1998).
Hamilton, J.A., “GM-CSF in inflammation and autoimmunity,”Trends Immunol23(8):403-408 (2002).
Hoogenboom, H.R., “Designing and optimizing library selection strategies for generating high-affinity antibodies,”Trends Biotech15(2):62-70 (1997).
Rathanaswami et al., “Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8,”Biochem Biophys Res Comm334(4):1004-1013 (2005).
Schön et al., “Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice,”J Invest Dermatology114(5):976-983 (2000).
Yamashita et al., “Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF),”Cell Immunol219(2):92-97 (2002).
D L Bratton, Q Hamid, M Boguniewicz, D E Doherty, J M Kailey, and D Y Leung “Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis” J Clin Invest.; 95(1): 211-218, Jan. 1995.
Elizabeth C. Cates, Ramzi Fattouh, Jennifer Wattie, Mark D. Inman, Susanna Goncharova, Anthony J. Coyle, José-Carlos Gutierrez-Ramos and Manel Jordana Intranasal Exposure of Mice to House Dust Mite Elicits Allergic Airway Inflammation via a GM-CSF-Mediated Mechanism The Joumal of Immunology, 173: pp. 6384-6392, 2004.
Ohta K, Yamashita N, Tajima M, Miyasaka T, Nakano J, Nakajima M, Ishii A, Horiuchi T, Mano K, Miyamoto T. “Diesel exhaust particulate induces airway hyperresponsiveness in a murine model: essential role of GM-CSF” J Allergy Clin Immunol.;104(5): pp. 1024-1030, Nov. 1999.
R J Bischof, D Zafiropoulos, J A Hamilton, and I K Campbell “Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: evidence of macrophage infiltration and local proliferation” Clin Exp Immunol.; 119(2): 361-367; Feb. 2000.
Ian K Campbell, Alison Bendele, David A Smith, John A Hamilton Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in miceAnn Rheum Dis; 56:364-368 Jun. 1997.
Andrew D Cook, Emma L Braine, Ian K Campbell, Melissa J Rich and John A Hamilton “Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease”Arthritis Res, 3:293-298, 2001.
Yuan H. Yang , John A. Hamilton “Dependence of interleukin-1-induced arthritis on granulocyte-macrophage colony-stimulating factor” vol. 44 Issue 1, pp. 111-119, Jan. 25, 2001.
M K Gorny, V Gianakakos, S Sharpe, and S Zolla-Pazner “Generation of human monoclonal antibodies to human immunodeficiency virus” PNAS vol. 86 No. 5 1624-1628, Mar. 1, 1989.
Tracey L. Bonfield, Mani S. Kavuru and Mary Jane Thomassen “Anti-GM-CSF Titer Predicts Response to GM-CSF Therapy in Pulmonary Alveolar Proteinosis” vol. 105, Issue 3, pp. 342-350, Dec. 2002.
Song XY et al., Coming of age: Anti-cytokine therapies,Mol Interv. Feb. 2002;2(1):36-46.
Weiner LM, Fully human therapeutic monoclonal antibodies,J Immunother. Jan.-Feb. 2006;29(1):1-9.
Enzler et al., Chapter 21. Granulocyte-macrophage colony-stimulating factor, In: Thomson et al., eds., The Cytokine Handbook, 4th Edition, Elsevier Science Ltd. 2003:503-524.
GENBANK Submission; NIH/NCBI, Accession No. NP—000749; Johnson et al.; Dec. 13, 2010.
GENBANK Submission; NIH/NCBI, Accession No. NP—034099; Choi et al.; Dec. 5, 2010.
GENBANK Submission; NIH/NCBI, Accession No. NP—001028121; Hutchinson et al.; Sep. 9, 2010.
GENBANK Submission; NIH/NCBI, Accession No. AAA52578.1; Lee et al.; Nov. 8, 1994.
GENBANK Submission; NIH/NCBI, Accession No. CAA26820.1; Gough et al.; Sep. 24, 2008.
GENBANK Submission; UniProtein, Accession No. B0KWQ4; Antonellis et al.; Nov. 30, 2010.
BLAST (Basic Local Alignment Search Tool) results for comparison of sequences AAA52578.1 and CAA26820.1. Search performed on Mar. 9, 2010. 3 pages.
Brown et al., Mapping of human granulocyte-macrophage-colony-stimulating-factor domains interacting with the human granulocyte-macrophage-colony-stimulating-factor-receptor alpha-subunit. Eur J Biochem. Nov. 1, 1994;225(3):873-80.
Dempsey et al., Monoclonal antibodies that recognize human granulocyte-macrophage colony-stimulating factor and neutralize its bioactivity in vitro. Hybridoma. Dec. 1990;9(6):545-58. Abstract only.
Jakobovits et al., From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol. Oct. 2007;25(10):1134-43.
Nice et al., Human granulocyte-macrophage colony-stimulating factor (hGM-CSF): identification of a binding site for a neutralizing antibody. Growth Factors. 1990;3(2):159-69. Abstract only.
Scott et al., A phase i dose-escalation study of bibh 1 in patients with advanced or metastatic fibroblast activation protein positive cancer. 2001 ASCO Annual Meeting. Proc Am Soc Clin Oncol. 2001;20:Abstract 1028.
Shanafelt et al., The amino-terminal helix of GM-CSF and IL-5 governs high affinity binding to their receptors. EMBO J. Dec. 1991;10(13):4105-12.
Short et al., Contribution of ant
Evec Inc.
Shafer Shulamith H
Wolf Greenfield & Sacks P.C.
LandOfFree
Human monoclonal antibody binding to hGM-CSF and its antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibody binding to hGM-CSF and its antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibody binding to hGM-CSF and its antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682944